Developing new agents to activate hidden HIV cells
Official title: Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
Run by University Hospital, Montpellier · NCT06441123 · Data updated 2026-11-12
This study is testing new treatments that aim to wake up hidden HIV cells in people on antiretroviral therapy to see if it helps the immune system get rid of the virus for good.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Status | Recruiting |
| Started | February 10, 2025 |
| Main results expected | February 10, 2027 |
| Study ends | February 10, 2027 |
| Registry record updated | February 24, 2025 |
| Trial ID | NCT06441123 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are HIV-positive individuals aged 18 or older, on ART, with an undetectable viral load for over 12 months and a history of very low CD4 counts.
✕Probably not a fit
Patients who are not on antiretroviral treatment or have a history of cancer within the last five years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the development of new latency-reversing agents (LRAs) that specifically target the Tat viral protein to activate dormant HIV cells in individuals on antiretroviral therapy (ART). By waking up these hidden cells, the goal is to enable the immune system to eliminate the virus, contributing to a potential cure for HIV. The study involves collecting blood samples from HIV-positive individuals with a history of low CD4 counts and undetectable viral loads, followed by laboratory analysis of immune cells treated with the new LRAs. The effectiveness of these agents will be measured through viral RNA and protein detection methods.
Why it matters
Potential benefit: If successful, this approach could lead to a breakthrough in HIV treatment by potentially eliminating hidden reservoirs of the virus.
How similar studies have gone: Other studies have shown promise with similar approaches targeting HIV latency, but this specific targeting of the Tat protein is a novel strategy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 years or older * HIV-positive * On ART (antiretroviral therapy) * HIV-1 RNA undetectable for more than 12 months * Nadir CD4 count \< 200/µL Exclusion Criteria: * Lack of antiretroviral treatment * Immunosuppressive treatments * History of cancer less than 5 years old * Pregnant or breast-feeding women * Persons protected by law (under guardianship or curators), persons under court protection * Participating in another research project with an ongoing exclusion period * Refusal to participate in research * Subject not affiliated to a social security scheme, or not benefiting from such a scheme.
Where it's running
-
CHU de MONTPELLIER
Montpellier, France Recruiting
Study contacts
- Study coordinator: Alain MAKINSON, Pr
- Email: a-makinson@chu-montpellier.fr
- Phone: 04 67 33 83 40
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Screen2Prevent: HIV screening for teens and young adults in emergency departments
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.